EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Opportunities in Overcoming Premature Termination Codons in Epidermolysis Bullosa via Translational Readthrough

Kathleen L Miao, Ryan Huynh, David Woodley, Mei Chen

Cells · 2025

DOI: 10.3390/cells14151215 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Kathleen L Miao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Hauptthemen laut MEDLINE: Codon, Nonsense, Epidermolysis Bullosa, Protein Biosynthesis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAMS NIH HHS, Congressionally Directed Medical Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermolysis Bullosa (EB) comprises a group of inherited blistering disorders caused by pathogenic variants in genes essential for skin and mucosal integrity. Nonsense mutations, which generate premature termination codons (PTCs), result in reduced or absent protein expression and contribute to severe disease phenotypes in EB. Readthrough therapies, which may continue translation past PTCs to restore full-length functional proteins, have emerged as promising approaches. This review summarizes findings from preclinical studies investigating readthrough therapies in EB models, clinical studies demonstrating efficacy in EB patients, and emerging readthrough agents with potential application to EB. Preclinical and clinical studies with gentamicin have demonstrated restored type VII collagen and laminin-332 expression, leading to measurable clinical improvements. Parallel development of novel compounds—including aminoglycoside analogs (e.g., ELX-02), translation termination factor degraders (e.g., CC-90009, SRI-41315, SJ6986), tRNA post-transcriptional inhibitors (e.g., 2,6-diaminopurine, NV848), and nucleoside analogs (e.g., clitocine)—has expanded the therapeutic pipeline. Although challenges remain regarding toxicity, codon specificity, and variable protein restoration thresholds, continued advances in molecular targeting and combination therapies offer the potential to establish readthrough therapies as localized or systemic treatments addressing both cutaneous and extracutaneous disease manifestations in EB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Codon, NonsenseEpidermolysis BullosaProtein BiosynthesisHumansAnimals

Stichwörter der Autor:innen

aminoglycosidesepidermolysis bullosagentamicinnonsense suppression therapypremature termination codonreadthrough therapy

Substanzen

Codon, Nonsense

Autor:innen und Institutionen

  • Department of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

Förderung

  • NIH HHS
  • NIAMS NIH HHS
  • Congressionally Directed Medical Research Program
  • Epidermolysis Bullosa Research Partnership and Epidermolysis Bullosa Medical Research Foundation
  • Eloxx Pharmaceuticals

Zitieren

APA

Miao, K. L., Huynh, R., Woodley, D., & Chen, M. (2025). Therapeutic Opportunities in Overcoming Premature Termination Codons in Epidermolysis Bullosa via Translational Readthrough. Cells. https://doi.org/10.3390/cells14151215

Vancouver

Miao KL, Huynh R, Woodley D, Chen M. Therapeutic Opportunities in Overcoming Premature Termination Codons in Epidermolysis Bullosa via Translational Readthrough. Cells. 2025. doi:10.3390/cells14151215

BibTeX
@article{Miao2025,
  author = {Miao, Kathleen L and Huynh, Ryan and Woodley, David and Chen, Mei},
  title = {Therapeutic Opportunities in Overcoming Premature Termination Codons in Epidermolysis Bullosa via Translational Readthrough},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14151215}
}
Kostenlos starten →